🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Health Concern

Cases of gonorrhoea are escalating globally, with figures suggesting in excess of 82 million infections per year. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on results detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced positive views. Having a single-dose, oral treatment like this is seen as a "game-changer" for public health efforts. This is considered vital to reduce the burden of the disease for people and to halt the transmission of untreatable gonorrhoea around the world.